Andere talen Galecto, Inc.

Aandelen

GLTO

US36322Q1076

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,7048 ^USD	+5,37%		+3,42%	-2,11%

08/03	Galecto, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	Galecto-aandelen klimmen na positieve resultaten van onderzoek naar behandeling van beenmergaandoeningen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	21/12
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis	21/12
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	21/12
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)	23-10-23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial	23-10-23
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23-10-23
Galecto Announces Plans to Explore Strategic Alternatives	26-09-23
Galecto to Explore Strategic Options, to Reduce Workforce	26-09-23
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	26-09-23
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	26-09-23
Galecto Announces Plans to Explore Strategic Alternatives	26-09-23
Galecto to Present at Investor Conferences in September	31-08-23
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	15-08-23
Sector Update: Health Care Stocks Easing Tuesday Afternoon	15-08-23
Top Midday Decliners	15-08-23
Galecto to End Lung Disease Drug Development After Trial Failed to Meet Primary Endpoint; Shares Fall	15-08-23
Galecto to discontinue development of lung disease treatment	15-08-23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis	15-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Galecto, Inc.

Aandelen

GLTO

US36322Q1076

Andere talen

Filters